Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications
Complex Psychiatry · 2019 · 5 (Suppl. 1) · 1-26
DOI: 10.1159/000492332 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Complex Psychiatry, online erschienen am 26.09.2018. Verfasst von Kazunari Yoshida und 1 weiteren Autor:innen. Beteiligte Einrichtung: Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.
Abstract (Originalsprache)
Numerous genetic variants have been shown to be associated with antipsychotic response and adverse effects of schizophrenia treatment. However, the clinical application of these findings is limited. The aim of this narrative review is to summarize the most recent publications and recommendations related to the genetics of antipsychotic treatment and shed light on the clinical utility of pharmacogenetics/pharmacogenomics (PGx). We reviewed the literature on PGx studies with antipsychotic drugs (i.e., antipsychotic response and adverse effects) and commonly used commercial PGx tools for clinical practice. Publications and reviews were included with emphasis on articles published between January 2015 and April 2018. We found 44 studies focusing on antipsychotic response and 45 studies on adverse effects (e.g., antipsychotic-induced weight gain, movement disorders, hormonal abnormality, and clozapine-induced agranulocytosis/granulocytopenia), albeit with mixed results. Overall, several gene variants related to antipsychotic response and adverse effects in the treatment of patients with schizophrenia have been reported, and several commercial pharmacogenomic tests have become available. However, further well-designed investigations and replication studies in large and well-characterized samples are needed to facilitate the application of PGx findings to clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
- Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Förderung
- NIMH NIH HHS
Zitieren
APA
Yoshida, K., & Müller, D. J. (2019). Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. Complex Psychiatry, 5(Suppl. 1), 1-26. https://doi.org/10.1159/000492332
Vancouver
Yoshida K, Müller DJ. Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. Complex Psychiatry. 2019;5(Suppl. 1):1-26. doi:10.1159/000492332
BibTeX
@article{Yoshida2019,
author = {Yoshida, Kazunari and Müller, Daniel J},
title = {Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications},
journal = {Complex Psychiatry},
year = {2019},
volume = {5},
number = {Suppl. 1},
pages = {1--26},
doi = {10.1159/000492332}
}
EUVIMED